Skip to content

Application of intranasal dexmedetomidine in general anesthesia

Effects of preoperative intranasal dexmedetomidine on perioperative general anesthetics requirements

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOC-14005537
Enrollment
Unknown
Registered
2014-11-12
Start date
2014-11-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia

Interventions

Control:Intranasal and intravenous saline
Intranasal dexmedetomidine:Intranasal dexmedetomidine and intravenous saline
Intravenous dexmedetomidine:Intranasal saline and intravenous dexmedetomidine

Sponsors

The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 55 Years

Inclusion criteria

Inclusion criteria: Aged 40-55 yr patients who scheduled for elective hysterectomy with ASA physical status I.

Exclusion criteria

Exclusion criteria: BMI larger than 30 kg/m2, heart diseases, hypertension, nasal diseases, recent use of sedative and analesic drugs, alcoholabuse, cerebral and mental illness patients.

Design outcomes

Primary

MeasureTime frame
Effect-site concentration of propofol in induction;Lowest effect-site concentration of propofol in maintenance;Highest effect-site concentration of propofol in maintenance;Propofol requirements in maintenance;Lowest effect-site concentration of remifentanil in maintenance;Highest effect-site concentration of remifentanil in maintenance;Remifentanil requirements in maintenance;Time to the first postoperative sufentanil dose;Sufentanil requirements 24h following surgery;

Secondary

MeasureTime frame
BIS values before target-controlled infused remifentanil;Number of patients required atropine and phenylephrine;The incidence of postoperative nausea and vomiting;

Countries

China

Contacts

Public ContactDong-hua Shao
13805281211@163.com+86 0511-88915960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026